Form 4: TPG Affiliates Boost Stake in Sionna Therapeutics with $950K Share Purchase

TPG GP A, LLC, a significant shareholder and director of Sionna Therapeutics, Inc., increased its beneficial ownership by acquiring 60,000 shares of common stock for approximately $950,400.

Summary

• TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, reported a change in beneficial ownership of Sionna Therapeutics, Inc. common stock.
• On June 27, 2025, TPG GP A, LLC acquired 60,000 shares of Sionna Therapeutics Common Stock at a price of $15.84 per share.
• The total value of this acquisition was $950,400.
• Following this transaction, the reporting persons indirectly beneficially own a total of 6,744,962 shares of Sionna Therapeutics Common Stock.
• This ownership is held through TPG Funds, specifically The Rise Fund Sling, L.P. (5,536,598 shares) and The Rise Fund Sling II, L.P. (1,208,364 shares).
• The reporting persons, including James G. Coulter and Jon Winkelried, are deemed to beneficially own these securities to the extent of their pecuniary interests in the TPG Funds.

Sentiment

Score: 8

Explanation: The insider purchase by a major institutional investor and directors signals strong confidence in the company's future, which is a highly positive indicator for investors.

Positives

• A significant insider purchase of 60,000 shares by TPG GP A, LLC, indicating confidence in Sionna Therapeutics' future prospects.
• The acquisition price of $15.84 per share suggests management and major shareholders believe the stock is undervalued or poised for growth at this price point.
• The transaction increases the total indirect beneficial ownership of the reporting persons to 6,744,962 shares, reinforcing their long-term commitment to the company.

Negatives

• No specific negatives are disclosed in this Form 4 filing.

Risks

• The beneficial ownership is indirect, held through a complex structure of TPG entities and funds, which may complicate direct shareholder influence or understanding of full exposure.
• Reporting persons disclaim beneficial ownership beyond their pecuniary interest, which could limit their direct accountability for the full block of shares.

Future Outlook

Not applicable. This Form 4 reports a past transaction and does not provide forward-looking statements or guidance.

Management Comments

• Each of James G. Coulter and Jon Winkelried own entities that control TPG GP A, LLC (together with Messrs. Coulter and Winkelried, the 'Reporting Persons'), which is the managing member of each of (i) TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., and (ii) Alabama Investments (Parallel) GP, LLC, which is the general partner of each of (a) Alabama Investments (Parallel), LP, (b) Alabama Investments (Parallel) Founder A, LP and (c) Alabama Investments (Parallel) Founder G, LP, which, collectively with TPG Group Holdings (SBS), L.P., Alabama Investments (Parallel), LP and Alabama Investments (Parallel) Founder A, LP, holds 100% of the shares of Class B common stock (which represents a majority of the combined voting power of the common stock) of TPG Inc.
• Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds.
• Each of the TPG Funds and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any.
• Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
• The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.

Industry Context

This transaction highlights continued investment by a major private equity firm, TPG, in the biotechnology sector, specifically Sionna Therapeutics. Insider purchases by significant institutional investors like TPG often signal confidence in a company's long-term prospects, especially in capital-intensive industries like biotech where R&D success and market adoption are critical. This could be seen as a vote of confidence in Sionna's pipeline or strategic direction.

Comparison to Industry Standards

• Insider buying, particularly by large institutional investors or directors, is generally viewed as a positive signal across industries, as it suggests those with the most intimate knowledge of the company believe its stock is undervalued or has significant upside potential.
• While specific comparable companies or projects are not detailed in this Form 4, the action aligns with a common investment strategy where major shareholders increase their stake when they perceive a favorable risk-reward profile. For example, similar insider purchases have been observed in other biotech firms like Moderna (MRNA) or BioNTech (BNTX) during key development phases, signaling internal confidence.
• The purchase price of $15.84 per share provides a benchmark for the reporting persons' valuation of Sionna Therapeutics at the time of the transaction.

Related Party Transactions

• The acquisition of 60,000 shares of Sionna Therapeutics Common Stock by TPG GP A, LLC, an entity controlled by directors James G. Coulter and Jon Winkelried, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Likely to view the insider purchase positively, as it suggests confidence from major investors and directors, potentially leading to increased investor interest and share price appreciation.
• Employees: May perceive increased stability and confidence in the company's long-term strategy.
• Creditors: Could view the increased insider stake as a sign of financial stability and commitment, potentially improving creditworthiness perception.

Next Steps

• Monitor future SEC filings (e.g., subsequent Form 4s) for further changes in beneficial ownership by TPG or other insiders.
• Observe Sionna Therapeutics' stock performance following this disclosure for market reaction.
• Analyze Sionna Therapeutics' upcoming financial reports and clinical trial updates for developments that might justify this insider confidence.

Key Dates

Recommendation

Keywords

Sionna Therapeutics, SION, TPG, TPG GP A, LLC, James G. Coulter, Jon Winkelried, insider purchase, stock acquisition, beneficial ownership, SEC Form 4, investment, biotechnology, pharmaceutical